# WATCHMAN FLX™ CT Study

> **NCT05324371** · NA · COMPLETED · sponsor: **Boston Scientific Corporation** · enrollment: 25 (actual)

## Conditions studied

- The Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial Fibrillation

## Interventions

- **DEVICE:** Watchman FLX Device

## Key facts

- **NCT ID:** NCT05324371
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-09
- **Primary completion:** 2024-05-30
- **Final completion:** 2025-01-23
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05324371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05324371, "WATCHMAN FLX™ CT Study". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05324371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*